InspireMD (NSPR) filed its FY2025 10-K on March 18, 2026. The company has a real structural tailwind: CREST-2 proved carotid artery stenting superior to medical management for asymptomatic patients (NEJM, p=0.02), CMS coverage is already in place, and NSPR holds the only FDA-approved MicroNet-equipped carotid stent in the U.S. Strip out cash and the market is paying $30M enterprise value for that franchise. The filing surfaces three problems the $5 analyst consensus hasn't fully priced.

The Business

InspireMD makes carotid stents. The core technology is a MicroNet mesh sleeve that wraps the stent during deployment, trapping embolic debris before it reaches the brain. C-GUARDIANS trial data shows the lowest 30-day and 1-year adverse event rates of any major carotid stent comparator. CGuard Prime received FDA PMA approval June 23, 2025 — the first and currently only MicroNet-equipped carotid stent approved for the U.S. market. Commercial launch followed in July 2025.

The addressable market structurally expanded. CMS expanded coverage to asymptomatic and standard-risk patients in October 2023. In November 2025, CREST-2 published in NEJM: CAS combined with medical therapy achieved a 2.8% primary outcome rate versus 6.0% for medical therapy alone (p=0.02). Carotid endarterectomy did not reach statistical significance (p=0.24). The finding is clean, NIH-sponsored, and peer-reviewed. It creates a defensible basis for the ≈80,000 asymptomatic CAS-eligible U.S. patients per year who were previously managed medically.

What the 10-K Shows

FY2025 revenue: $8.98M (+28%). Gross margin: 29.5%, up from 21.5% (+8 percentage points). Net loss: $(48.8M). Operating cash burn: $35M, up from $22M in 2024. Total liquid assets: $54.2M (cash + marketable securities).

Only six months of U.S. revenue appeared in FY2025. H2 2025 generated $1.4M incremental North American revenue from CGuard Prime against $16.6M in S&M spend — the full U.S. salesforce buildout with half a year of output.

The going concern is formal. Both management and auditor (Kesselman & Kesselman, PwC Israel member firm) issued going concern language despite $54.2M in liquid assets. The reason: projected 2026 operating burn (≈$40M+) exhausts current cash within 12 months. The company lists its resolution plans — commercialization, equity raises, warrant exercises, strategic partnerships — but provides no assurance they will succeed.

Strip out cash and the enterprise value is $30M ($1.81 stock − $1.16/share cash = $0.65/share × 46.8M shares). The market is paying $30M for the CGuard Prime franchise, the FDA PMA, and the entire pipeline. That is either an interesting entry or a fair reflection of the dilution ahead. The answer depends on three things the filing reveals.

Three Problems

1. The Israel Tariff Is Reversing the Margin Story

The gross margin improvement from 21.5% to 29.5% is the most compelling number in the bull case. It reflects the mix shift toward U.S. direct sales at higher ASPs versus international distributor pricing. The problem: a 15% Section 122 tariff on all Israeli goods took effect February 24, 2026. All NSPR manufacturing is in Israel. The North Carolina transfer to Aptyx is underway but not operational, with no timeline disclosed.

This is not hypothetical. InMode (INMD) is an Israeli medical device company with an identical manufacturing footprint — 100% Israeli production, substantial U.S. revenue. On their Q4 2025 earnings call (February 10, 2026): "15% all imports Israel affect gross margin neighborhood 75%." Historical INMD margins were ≈79%. The Section 122 tariff imposed a 200-400bps headwind.

No U.S.-Israel FTA exemption exists for this tariff. The FTA eliminates MFN tariffs; Section 122 operates under separate statutory authority applied uniformly to all countries. Medical devices are not in the exempted product list (pharmaceuticals, critical minerals, energy, semiconductors are). The FTA provides zero cover.

At NSPR's current scale — $8.98M revenue, 29.5% margin, $2.65M gross profit — a 300bps tariff headwind reduces gross profit by roughly $1M. As U.S. revenue scales in 2026, the absolute dollar impact grows with every unit shipped from Israel. The margin expansion story remains intact on a multi-year horizon (U.S. direct sales vs. distributor, Aptyx transfer eventually), but the near-term trajectory in 2026 is impaired. The most exciting number in the filing has a headwind attached to it that was not there in FY2025.

2. Medtronic Entered the Same Procedural Indication at the Same Time

NSPR's 10-K competitive section names Abbott, Boston Scientific, Medtronic, Cordis, and Terumo. It does not mention NeuroGard. Medtronic launched the NeuroGard IEP (inner embolic protection) carotid stent in the U.S. in Q2 FY2026 — the same quarter as CGuard Prime's commercial launch. From MDT's November 2025 earnings call: "Peripheral vascular, grew low single digits, expect improve as launch NeuroGard IEP carotid stent."

NeuroGard is a direct CAS competitor. It uses inner embolic protection to catch debris during transfemoral stent deployment — the same procedural indication as CGuard Prime. This is not TCAR (Boston Scientific/Silk Road's approach) and not carotid endarterectomy. This is CAS versus CAS.

MDT has 40,000+ employees and cardiovascular representatives walking catheterization labs where CGuard Prime needs to be sold. NSPR's clinical differentiation is real — MicroNet mesh is distinct from MDT's IEP design, and C-GUARDIANS outcomes data supports it. But physician adoption requires education, hospital contracting, and reimbursement processes that take 6-18 months per account. MDT can compress that cycle where it already has relationships. NSPR spent $16.6M on S&M to generate $1.4M of U.S. revenue. Sales cycle length explains much of that gap; a better-resourced entrant in the same market explains some of the rest.

Boston Scientific (via Silk Road ENROUTE) is a different kind of competitor — TCAR requires surgical neck access, not transfemoral catheterization, and is performed by vascular surgeons rather than interventional cardiologists. LMAT confirmed on their Q4 2025 call that CREST-2 has already started shifting asymptomatic patients from TCAR toward CAS — meaning BSX's TCAR buildout may actually be an indirect tailwind for NSPR's category. The near-term CAS-specific competitive risk is MDT, not BSX.

3. The COO Left Six Weeks Before a Critical Earnings Print

This does not appear in the 10-K. An 8-K filed after the annual report disclosed COO Shane Gleason's termination on February 27, 2026, effective April 1. At an $84M market cap company in the first year of its U.S. commercial launch, the COO runs the day-to-day execution that the market needs to see work.

Two reads: routine restructuring for U.S. commercial scaling, or an internal signal that the ramp is not tracking to plan. Gleason also sold 61,194 shares for $99K on February 2 — three weeks before the 8-K. On the other side: CEO Slosman received 1,114,792 RSU awards (≈$2.0M) on January 14, and CFO Lawless received 226,695 RSUs (≈$410K). Management is loading equity at current prices. The departure and the grant awards coexist — one signals execution concern, the other signals management conviction. The earnings call today is the first opportunity for explanation.

The Bull Case Is Also Structurally Sound

The three problems above are material. They do not kill the thesis.

CREST-2 is a genuine, independent structural catalyst. The asymptomatic CAS-eligible patient pool is multiples larger than the symptomatic and high-surgical-risk patients that constituted the prior addressable market. The CMS NCD is already in place. LMAT's Q4 2025 call confirmed the market shift is beginning to flow through to actual procedures. The structural market expansion requires no additional regulatory approval, no clinical success — it is already law and published science.

The dilution wall has structure. Series K warrants ($17.9M gross at $1.38 strike) trigger at the end of Q3 2026. At $1.81, they are in-the-money. The pre-funded warrants (43M shares at ≈$0.001) represent economic exposure, not liquidation pressure — they are held by insiders who retain alignment. The ATM ($75M, barely drawn) is ammunition. Going concern language will suppress the stock until the commercial ramp makes it unnecessary — but that is the opportunity, not the threat, if execution follows.

The EPS beat trend is accelerating: flat, +12.8%, +27.6% over the last three quarters. Either the model is improving or estimates are too conservative. The filing shows gross margin expanding even before U.S. direct sales scale. The operating leverage story is real — it just requires the revenue ramp to arrive.

What the Market Is Pricing

At $1.81 with $1.16/share in cash, enterprise value is $30M. In a two-scenario framework (bull $3.00, bear $0.75), the market's implied bull probability solves to ≈47%.

Three-scenario model (18-month horizon):

Probability-weighted EV: 0.35 × $3.00 + 0.25 × $1.60 + 0.40 × $0.75 = $1.75

Current price $1.81. EV $1.75. Marginally negative. The market at 47% implied bull probability is pricing this roughly 8-12 percentage points above where the fundamentals sit. Not a dramatic mispricing, but the divergence is consistently in the same direction: the bear case is modestly underpriced.

The $5 analyst consensus requires near-dominance of the U.S. CAS market (≈40%+ share) plus continued multiple expansion plus limited dilution. At 15-25% realistic U.S. CAS penetration, steady-state revenue is $17-26M. At $40M+ required for operating profitability, the math requires either the S&M investment rationalized dramatically as revenue scales, or revenue growth far exceeds the realistic market share range. The $5 target is the outcome of an optimistic scenario, not a base case.

The Entry

Pre-print at $1.81: no. Risk/reward is 1.12:1 ($1.19 reward, $1.06 risk). EV is marginally negative. Kelly is negative even at 55% probability because downside asymmetry is too severe.

The 3:1 risk/reward entry level is $1.31 (mathematical: bull target $3.00, bear floor $0.75). That price appears only on earnings disappointment or a broad selloff.

Post-strong print (Q4 U.S. >$1.5M) at $2.00-2.25: small starter. Revised EV at updated probabilities (≈$2.53) is positive versus entry price, but Kelly remains negative and the going concern hard-caps sizing.

Real sizing entry is post-Q1 2026 confirmation. Two consecutive U.S. revenue beats de-risk commercial execution, going concern language likely softens, and institutional capital can re-engage. That is the entry, not today.

The Decision Point

Q4 2025 U.S. CGuard Prime revenue is the number. The 10-K gives full-year data only; H2 2025 generated $1.4M North American revenue across two quarters. The quarterly breakdown is in today's earnings release.

Above $1.5M Q4 U.S.: commercial ramp is beginning. Bull probability rises to 55-60%. Watch for entry at $2.00-2.20 post-print.

Below $1.0M Q4 U.S.: bear math dominates. Going concern and dilution are the story. Pass.

Between $1.0-1.5M: wait for Q1 2026 confirmation before any position.

One number. Today.

Evidence